While the recent presentation didn't have any major announcements, I thought it was generally optimistic. The have largely completed capital investments, have completed WHO accreditations (now getting country approvals), have set up a US company, and are now focusing on the swab development, marketing endeavours, and agreements. They have cash in the bank, and have realised that the Covid swab (via China) will provide them with a further buffer to grow and explore business/core opportunities. In my mind, this is a hold for several more years.
AT1 Price at posting:
6.5¢ Sentiment: Hold Disclosure: Held
